Kala Bio secures exclusive US distribution rights for Virotek ophthalmology genetic testing program

KALA BIO, Inc.

Exclusive 5-year distribution deal with Virotek for ophthalmology genetic testing/screening program in US, effective Sept 3, 2026.
Profit split 50/50 after Virotek recovers COGS; Kala handles commercial development, Virotek delivery/administration.
Exclusivity conditioned on Kala meeting milestone by Sept 3, 2027; failure converts to non-exclusive after 30-day cure.
Kala gets right of first refusal on any sale/license of Virotek's ophthalmology products; term renewable by mutual agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.